PeptideStack
5.2kquestions
20kanswers
220users

Would you re-test semaglutide after twelve weeks at minus 80 °C, or accept the original certificate?

Asked 1 Apr 2026Modified 3 months agoViewed 2.7k times
8

Concretely: semaglutide · twelve weeks · minus 80 °C.

I want to decide this in advance so that I am not deciding it under pressure later.

Assume I will follow the plan I write down, so I would like it to be a good one.

What would you do, and what would make you change course?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
shareeditfollowflag
RP
askedravi_pillai12k171 Apr 2026
6Add the gradient and the column if you have them — half the answer depends on those. – v_ramaswamy 9 months ago
7Same question came up on a different supplier and the answer was entirely about the method. – orla_ferriter 13 days ago
add a comment

4 Answers

Accepted answer first, then by votes
44

Accepted answer

twelve weeks is 84 days. minus 80 °C is 85 kelvin below a refrigerator, and below the glass transition of a lyophilised cake the ten-degree rule of thumb stops applying at all — solid-state chemistry is not slow liquid chemistry, it is a different regime, and the failure modes that survive it are mechanical rather than chemical. Compare that against what the certificate covers, which is the material as it left the laboratory on the date of analysis and nothing after it. That is short enough that a re-test is a stability study rather than a safety check — worth doing if you will publish the result, hard to justify if you will only reassure yourself. If you do re-test, send it for content as well as purity; the 84 days will have moved one of them further than the other.

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

Mass shifts and what they usually mean

Δ mass (Da)Most likely causeDistinguishing feature
+1Deamidation (Asn or Gln)New peak, slightly earlier retention
−17Loss of ammoniaOften with deamidation
−18Dehydration / succinimidepH-dependent, reversible
+16Oxidation (Met, Trp)Earlier retention, light-related
−128Missing Gln or LysDeletion sequence from synthesis
0Isomer: racemisation or scramblingSame mass, shifted retention

Put another way, if you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
DK
answered · acceptedDr_Tomas_Kral53k389 Apr 2026
Adding a vote because this deserves more of them. – RP_C18 10 days ago
2Same experience here, different supplier. – meniscus_film 2 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
52

Specifically, if a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

In practice, the sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

edited 13 May 2026 by anders_vestby — added a caveat about sampling

shareimprove this answerflag
AV
answeredanders_vestby8.5k161 May 2026
20

The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.

If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
TM
answeredtobias_maartens171k35820 Apr 2026
-2

Put another way, the failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
PM
answeredp_mkhize58k23812 May 2026

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.